FDA review – Patient Worthy

FDA Begins Review of uniQure Gene Therapy Candidate for Huntington’s Disease

Post author:Austin Newman
Post published:November 3, 2026
Post category:Huntington's disease

As reported by the Manila Times, the FDA has formally accepted uniQure’s biologics license application for ifezuntirgene inilparvovec (AMT-130), an experimental gene therapy being developed for people living with Huntington’s…

FDA Review Raises Questions About Replimune’s Melanoma Therapy Ahead of Advisory Committee Vote

Post author:Austin Newman
Post published:July 29, 2026
Post category:Melanoma

As reported on Reuters, Replimune’s experimental cancer treatment RP1 is facing increased regulatory scrutiny after U.S. Food and Drug Administration (FDA) reviewers expressed concerns about whether current clinical data adequately…

FDA Begins Review of uniQure Gene Therapy Candidate for Huntington’s Disease

FDA Review Raises Questions About Replimune’s Melanoma Therapy Ahead of Advisory Committee Vote

Let’s Work Together!

Keep Up to Date

Learn More